The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - Novartis (Inst); Pfizer (Inst)
Progression-free survival (PFS) and subgroups analyses of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs): Updated results from the phase II TALENT trial (GETNE 1509).
 
Jaume Capdevila
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Bayer; Eisai; Ipsen; Merck Serono; Novartis; Pfizer; Sanofi
Speakers' Bureau - Advanced Accelerator Applications; Amgen; Bayer; Eisai; Ipsen; Merck Serono; Novartis; Pfizer; Sanofi
Research Funding - AstraZeneca (Inst); Bayer (Inst); Eisai (Inst); Novartis (Inst); Pfizer (Inst)
 
Nicola Fazio
Honoraria - Ipsen; Novartis
Consulting or Advisory Role - Advanced Accelerator Applications; Ipsen; Merck Serono; MSD Oncology; Novartis/Ipsen; Pfizer
Research Funding - Merck Serono (Inst); Novartis (Inst)
 
Carlos López-López
Consulting or Advisory Role - Eisai; Ipsen; Merck Serono; Novartis; Pfizer; Sanofi
Speakers' Bureau - Eisai; Ipsen; Merck Serono; Novartis; Pfizer
 
Alexandre Teule
No Relationships to Disclose
 
Juan W. Valle
Honoraria - Ipsen
Consulting or Advisory Role - Agios; AstraZeneca; Delcath Systems; Genoscience Pharma; Incyte; Ipsen; Keocyt; Merck; Novartis; PCI Biotech; Pfizer; Pieris Pharmaceuticals; QED Therapeutics
Speakers' Bureau - Ipsen; Novartis
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Celgene; Nucana
 
Salvatore Tafuto
No Relationships to Disclose
 
Ana B. Custodio
Consulting or Advisory Role - Ipsen; MSD; Novartis; Pfizer
Research Funding - Ipsen (Inst); Pfizer (Inst)
 
Nicholas Reed
No Relationships to Disclose
 
Markus Raderer
Consulting or Advisory Role - Celgene; Eisai; Ipsen; Novartis
 
Enrique Grande
Consulting or Advisory Role - MSD, Pfizer, IPSEN
Research Funding - Pfizer, AstraZeneca, IPSEN (Inst)
 
Rocio Garcia-Carbonero
Honoraria - AstraZeneca (I); Boehringer Ingelheim (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); CELGENE (I); IPSEN; Lilly (I); MERCK; Merck (I); MSD; MSD (I); Novartis; Novartis (I); PFIZER; Pfizer (I); ROCHE; Roche (I); SERVIER
Consulting or Advisory Role - AstraZeneca (I); Boehringer Ingelheim (I); Bristol-Myers Squibb (I); IPSEN; Lilly (I); Merck Sharp & Dohme (I); MSD; Novartis (I); Pfizer (I); Roche (I)
Research Funding - PFIZER
Travel, Accommodations, Expenses - Amgen; Boehringer Ingelheim (I); Ipsen; Lilly (I); Merck; Novartis; Pfizer; Pfizer (I); Roche; Roche (I); Sanofi
 
Paula Jiménez-Fonseca
Other Relationship - IPSEN
 
Vicente Alonso
No Relationships to Disclose
 
Lorenzo Antonuzzo
No Relationships to Disclose
 
Andrea Spallanzani
No Relationships to Disclose
 
Alfredo Berruti
Consulting or Advisory Role - Janssen-Cilag
Speakers' Bureau - Janssen-Cilag
Research Funding - Astellas Pharma (Inst); Janssen-Cilag (Inst)
Travel, Accommodations, Expenses - Janssen-Cilag; Sanofi; Sanofi
 
Isabel Sevilla
No Relationships to Disclose
 
Adelaida La Casta Munoa
No Relationships to Disclose
 
Jorge Hernando
No Relationships to Disclose
 
Toni Ibrahim
Consulting or Advisory Role - Eisai
Speakers' Bureau - Eisai